# The Role of Endothelin-1 in Sickle Cell Disease

> **NCT02712346** · PHASE1 · COMPLETED · sponsor: **Augusta University** · enrollment: 26 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02712346
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02712346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02712346, "The Role of Endothelin-1 in Sickle Cell Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02712346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*